$67.33
-0.45-0.66%
At close: -
$68.48
1.151.71%
After Hours: 5:03 PM EDT
Comments
Loading...
GeneDx Holdings Analyst Ratings and Price Targets | NASDAQ:WGS | Benzinga
GeneDx Holdings Corp has a consensus price target of $86.57 based on the ratings of 7 analysts. The high is $118 issued by TD Cowen on January 7, 2025. The low is $45 issued by BTIG on July 31, 2024. The 3 most-recent analyst ratings were released by Jefferies, TD Securities, and Wells Fargo on May 9, 2025, May 1, 2025, and May 1, 2025, respectively. With an average price target of $89.33 between Jefferies, TD Securities, and Wells Fargo, there's an implied 30.45% upside for GeneDx Holdings Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Jefferies
TD Securities
Wells Fargo
Goldman Sachs
TD Cowen
1calculated from analyst ratings
Analyst Ratings for GeneDx Holdings
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/09/2025 | Buy Now | 16.82% | Jefferies | Tycho Peterson84% | → $80 | Upgrade | Hold → Buy | Get Alert |
| 05/01/2025 | Buy Now | 60.63% | TD Securities | Dan Brennan62% | $135 → $110 | Maintains | Buy | Get Alert |
| 05/01/2025 | Buy Now | 13.9% | Wells Fargo | Brandon Couillard21% | $105 → $78 | Maintains | Equal-Weight | Get Alert |
| 02/19/2025 | Buy Now | 16.82% | Goldman Sachs | Matthew Sykes63% | $70 → $80 | Maintains | Neutral | Get Alert |
| 01/07/2025 | Buy Now | 72.31% | TD Cowen | Dan Brennan62% | $75 → $118 | Maintains | Buy | Get Alert |
| 10/30/2024 | Buy Now | 2.22% | Goldman Sachs | Matthew Sykes63% | $54 → $70 | Maintains | Neutral | Get Alert |
| 10/30/2024 | Buy Now | 9.52% | Wells Fargo | Brandon Couillard21% | $34 → $75 | Maintains | Equal-Weight | Get Alert |
| 10/30/2024 | Buy Now | 38.73% | Craig-Hallum | Bill Bonello59% | $70 → $95 | Maintains | Buy | Get Alert |
| 10/24/2024 | Buy Now | 2.22% | Craig-Hallum | Bill Bonello59% | $46 → $70 | Maintains | Buy | Get Alert |
| 10/16/2024 | Buy Now | -21.14% | Goldman Sachs | Matthew Sykes63% | $32 → $54 | Maintains | Neutral | Get Alert |
| 08/27/2024 | Buy Now | -50.35% | Wells Fargo | Brandon Couillard21% | → $34 | Initiates | → Equal-Weight | Get Alert |
| 07/31/2024 | Buy Now | -26.99% | TD Cowen | Dan Brennan62% | $46 → $50 | Maintains | Buy | Get Alert |
| 07/31/2024 | Buy Now | -34.29% | BTIG | Mark Massaro72% | $35 → $45 | Maintains | Buy | Get Alert |
| 07/31/2024 | Buy Now | -32.83% | Craig-Hallum | Bill Bonello59% | $43 → $46 | Maintains | Buy | Get Alert |
| 07/31/2024 | Buy Now | -53.27% | Goldman Sachs | Matthew Sykes63% | $28 → $32 | Maintains | Neutral | Get Alert |
| 07/17/2024 | Buy Now | -59.11% | Goldman Sachs | Matthew Sykes63% | $12.5 → $28 | Maintains | Neutral | Get Alert |
| 07/10/2024 | Buy Now | -37.21% | Craig-Hallum | Bill Bonello59% | → $43 | Initiates | → Buy | Get Alert |
| 06/26/2024 | Buy Now | -48.89% | BTIG | Mark Massaro72% | $19 → $35 | Maintains | Buy | Get Alert |
| 04/30/2024 | Buy Now | -64.95% | TD Cowen | Dan Brennan62% | $14 → $24 | Maintains | Buy | Get Alert |
| 04/30/2024 | Buy Now | -72.25% | BTIG | Mark Massaro72% | $15 → $19 | Maintains | Buy | Get Alert |
| 04/22/2024 | Buy Now | -78.1% | BTIG | Mark Massaro72% | $11 → $15 | Maintains | Buy | Get Alert |
| 04/15/2024 | Buy Now | -83.94% | Goldman Sachs | Matthew Sykes63% | $6 → $11 | Maintains | Neutral | Get Alert |
| 11/01/2023 | Buy Now | -91.24% | Goldman Sachs | Matthew Sykes63% | $7 → $6 | Maintains | Neutral | Get Alert |
| 08/09/2023 | Buy Now | -89.78% | Goldman Sachs | Matthew Sykes63% | $8 → $7 | Maintains | Neutral | Get Alert |
| 07/24/2023 | Buy Now | -88.32% | Goldman Sachs | Matthew Sykes63% | $9 → $8 | Maintains | Neutral | Get Alert |
| 07/21/2023 | Buy Now | -88.32% | Goldman Sachs | Matthew Sykes63% | $9 → $8 | Maintains | Neutral | Get Alert |
| 05/15/2023 | Buy Now | -86.86% | Goldman Sachs | Matthew Sykes63% | $33 → $9 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for GeneDx Holdings (WGS) stock?
The latest price target for GeneDx Holdings (NASDAQ:WGS) was reported by Jefferies on May 9, 2025. The analyst firm set a price target for $80.00 expecting WGS to rise to within 12 months (a possible 16.82% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for GeneDx Holdings (WGS)?
The latest analyst rating for GeneDx Holdings (NASDAQ:WGS) was provided by Jefferies, and GeneDx Holdings upgraded their buy rating.
When was the last upgrade for GeneDx Holdings (WGS)?
The last upgrade for GeneDx Holdings Corp happened on May 9, 2025 when Jefferies raised their price target to $80. Jefferies previously had a hold for GeneDx Holdings Corp.
When was the last downgrade for GeneDx Holdings (WGS)?
There is no last downgrade for GeneDx Holdings.
When is the next analyst rating going to be posted or updated for GeneDx Holdings (WGS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of GeneDx Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for GeneDx Holdings was filed on May 9, 2025 so you should expect the next rating to be made available sometime around May 9, 2026.
Is the Analyst Rating GeneDx Holdings (WGS) correct?
While ratings are subjective and will change, the latest GeneDx Holdings (WGS) rating was a upgraded with a price target of $0.00 to $80.00. The current price GeneDx Holdings (WGS) is trading at is $68.48, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
